Movement Alert｜Boston Scientific Falls 3.07% in Regular Trading, Repeated Price-Target Cuts Weigh on Sentiment

Market Focus

Yesterday

On October 13, Boston Scientific fell 3.07% in Regular Trading, trading at $42.545/share, with turnover of $149 million.

The clearest catalyst was renewed pressure from Wall Street target-price cuts. The most recent adjustment came on October 7, when Evercore ISI lowered its target price to $52 from $65.

That followed a series of downward revisions: Citigroup cut its target to $48 and kept a neutral rating on October 5, while Oppenheimer reduced its target to $65 from $85 in September. Although Boston Scientific still carried an average overweight rating and a mean target price of $58.79 in the October 7 analyst snapshot, the succession of lower targets suggests a more cautious near-term view on the company’s recovery trajectory ahead of its next earnings report on October 28.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigermarketb.com/news/1168179115"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168179115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168179115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-13 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168179115","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Boston Scientific Falls 3.07% in Regular Trading, Repeated Price-Target Cuts Weigh on Sentiment","media":"Market Focus","content":"<p><p>On October 13, Boston Scientific fell 3.07% in Regular Trading, trading at $42.545/share, with turnover of $149 million.</p><p>The clearest catalyst was renewed pressure from Wall Street target-price cuts. The most recent adjustment came on October 7, when Evercore ISI lowered its target price to $52 from $65.</p><p>That followed a series of downward revisions: Citigroup cut its target to $48 and kept a neutral rating on October 5, while Oppenheimer reduced its target to $65 from $85 in September. Although Boston Scientific still carried an average overweight rating and a mean target price of $58.79 in the October 7 analyst snapshot, the succession of lower targets suggests a more cautious near-term view on the company’s recovery trajectory ahead of its next earnings report on October 28.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Boston Scientific Falls 3.07% in Regular Trading, Repeated Price-Target Cuts Weigh on Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Boston Scientific Falls 3.07% in Regular Trading, Repeated Price-Target Cuts Weigh on Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-13 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 13, Boston Scientific fell 3.07% in Regular Trading, trading at $42.545/share, with turnover of $149 million.</p><p>The clearest catalyst was renewed pressure from Wall Street target-price cuts. The most recent adjustment came on October 7, when Evercore ISI lowered its target price to $52 from $65.</p><p>That followed a series of downward revisions: Citigroup cut its target to $48 and kept a neutral rating on October 5, while Oppenheimer reduced its target to $65 from $85 in September. Although Boston Scientific still carried an average overweight rating and a mean target price of $58.79 in the October 7 analyst snapshot, the succession of lower targets suggests a more cautious near-term view on the company’s recovery trajectory ahead of its next earnings report on October 28.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1168179115","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168179115","pubTimestamp":1791902582,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 13, Boston Scientific fell 3.07% in Regular Trading, trading at $42.545/share, with turnover of $149 million.The clearest catalyst was renewed pressure from Wall Street target-price cuts....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"走势警报|波士顿科学常规交易中下跌3.07%，多次下调目标价打压市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"On October 13, Boston Scientific fell 3.07% in Regular Trading, trading at $42.545/share, with turnover of $149 million.The clearest catalyst was renewed pressure from Wall Street target-price cuts. The most recent adjustment came on October 7, when Evercore ISI lowered its target price to $52 from $65.That followed a series of downward revisions: Citigroup cut its target to $48 and kept a neutral rating on October 5, while Oppenheimer reduced its target to $65 from $85 in September. Although Boston Scientific still carried an average overweight rating and a mean target price of $58.79 in the October 7 analyst snapshot, the succession of lower targets suggests a more cautious near-term view on the company’s recovery trajectory ahead of its next earnings report on October 28.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}